.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB03_Afatinib.Afatinib

Information

Afatinib is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases, including EGFR (epidermal growth factor receptor). It is primarily used for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations and is approved for clinical use today.

Pharmacokinetics

Pharmacokinetic parameters in adult patients with advanced solid tumors or non-small cell lung cancer under fasting conditions.

References

1. Wind, S, et al., & Stopfer, P (2017). Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clinical pharmacokinetics 56(3) 235–250. DOI:10.1007/s40262-016-0440-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27470518

2. Nakao, K, et al., & Atagi, S (2019). Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. Scientific reports 9(1) 18202–None. DOI:10.1038/s41598-019-54804-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31796841

3. Freiwald, M, et al., & Staab, A (2014). Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. Cancer chemotherapy and pharmacology 73(4) 759–770. DOI:10.1007/s00280-014-2403-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24522402

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)